
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals Inc. is witnessing strong growth in its product revenues, particularly with Fanapt, which achieved a 27% year-over-year revenue increase to $29.3 million in Q2 25, followed by a 31% increase in Q3 25, placing its annualized run-rate near $120 million. The recent commercial launch of Ponvory has shown promising momentum, as evidenced by record new patient prescriptions and projected gross sales ramping from $9.4 million in 2027 to $172.8 million by 2034, supported by targeted therapy utilization increases. Furthermore, enhanced promotional efforts and prescriber awareness programs have successfully driven substantial growth in new patient prescriptions and overall prescription volume, indicating a positive trajectory for Vanda Pharmaceuticals' commercial strategy.
Bears say
Vanda Pharmaceuticals Inc. has reported a decline in net product sales, with revenues of $7.1 million in the second quarter of 2025, reflecting an 18% year-over-year decrease, despite a subsequent 20% growth in the third quarter. The company's revenue base is expected to face significant pressure as market exclusivity for its key products erodes by the end of 2027, compounded by anticipated declines in oral Fanapt sales due to competition from new therapies and changes in reimbursement dynamics. Additionally, the cessation of promotional activities for Ponvory by Johnson & Johnson in 2022 highlights concerns regarding the product’s commercial viability and revenue generation potential, further reinforcing the negative outlook for Vanda Pharmaceuticals.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares